KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.315 $0.440 Friday, 26th Apr 2024 GLMD stock ended at $0.392. This is 0.229% less than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.87% from a day low at $0.373 to a day high of $0.395.
90 days $0.300 $0.466
52 weeks $0.260 $5.63

Historical Galmed Pharmaceuticals Ltd. prices

Date Open High Low Close Volume
Jan 09, 2024 $0.430 $0.450 $0.423 $0.449 25 150
Jan 08, 2024 $0.445 $0.445 $0.421 $0.430 54 772
Jan 05, 2024 $0.450 $0.450 $0.430 $0.445 35 146
Jan 04, 2024 $0.434 $0.449 $0.420 $0.433 14 022
Jan 03, 2024 $0.440 $0.455 $0.430 $0.449 170 522
Jan 02, 2024 $0.450 $0.450 $0.421 $0.440 57 932
Dec 29, 2023 $0.448 $0.460 $0.420 $0.455 80 133
Dec 28, 2023 $0.470 $0.470 $0.420 $0.436 30 932
Dec 27, 2023 $0.420 $0.450 $0.420 $0.440 72 676
Dec 26, 2023 $0.408 $0.450 $0.395 $0.430 132 359
Dec 22, 2023 $0.378 $0.430 $0.370 $0.417 330 293
Dec 21, 2023 $0.400 $0.400 $0.331 $0.366 198 520
Dec 20, 2023 $0.378 $0.410 $0.364 $0.400 197 771
Dec 19, 2023 $0.398 $0.398 $0.378 $0.378 54 118
Dec 18, 2023 $0.370 $0.380 $0.356 $0.370 37 063
Dec 15, 2023 $0.350 $0.370 $0.350 $0.369 14 783
Dec 14, 2023 $0.380 $0.380 $0.317 $0.364 83 302
Dec 13, 2023 $0.336 $0.349 $0.310 $0.349 95 157
Dec 12, 2023 $0.354 $0.354 $0.330 $0.334 18 398
Dec 11, 2023 $0.360 $0.360 $0.332 $0.337 74 188
Dec 08, 2023 $0.410 $0.410 $0.332 $0.357 212 617
Dec 07, 2023 $0.395 $0.467 $0.381 $0.396 574 312
Dec 06, 2023 $0.400 $0.417 $0.380 $0.395 69 311
Dec 05, 2023 $0.390 $0.400 $0.378 $0.386 59 350
Dec 04, 2023 $0.370 $0.390 $0.353 $0.390 97 852
Click to get the best stock tips daily for free!

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica... GLMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT